Prelude Capital Management’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-139,534
| Closed | -$11.9M | – | 2317 |
|
|
2019
Q4 | $11.9M | Buy |
139,534
+131,588
| +1,656% | +$8.78M | 0.45% | 18 |
|
|
2019
Q3 | $397K | Buy |
+7,946
| New | +$317K | 0.02% | 584 |
|
|
2016
Q4 | – | Sell |
-1,818
| Closed | -$69K | – | 1904 |
|
|
2016
Q3 | $69K | Buy |
+1,818
| New | +$68.5K | 0.01% | 954 |
|
|
2016
Q2 | – | Sell |
-4,601
| Closed | -$146K | – | 1828 |
|
|
2016
Q1 | $146K | Buy |
+4,601
| New | +$150K | 0.02% | 643 |
|
|
2015
Q2 | – | Sell |
-2,900
| Closed | -$81K | – | 2196 |
|
|
2015
Q1 | $81K | Buy |
+2,900
| New | +$81.5K | 0.01% | 1098 |
|
|
2014
Q4 | – | Sell |
-2,600
| Closed | -$58K | – | 2269 |
|
|
2014
Q3 | $58K | Sell |
2,600
-400
| -13% | -$10.2K | 0.01% | 1347 |
|
|
2014
Q2 | $87K | Buy |
3,000
+200
| +7% | +$5.34K | 0.01% | 1148 |
|
|
2014
Q1 | $80K | Buy |
2,800
+1,900
| +211% | +$62.9K | 0.01% | 1117 |
|
|
2013
Q4 | $35K | Sell |
900
-8,100
| -90% | -$290K | 0.01% | 1218 |
|
|
2013
Q3 | $302K | Buy |
+9,000
| New | +$287K | 0.05% | 413 |
|
Other funds holding MDCO
Prelude Capital Management's MDCO Position: Q1 2020 in Review
Prelude Capital Management sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 139,534 shares — an estimated $11.9M sold.
Prelude Capital Management first reported a position in MDCO in Q3 2013 and held it in 10 quarters. The position peaked at $11.9M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Prelude Capital Management reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Prelude Capital Management sold 139,534 Medicines Co shares in Q1 2020, an estimated $11.9M.
- Prelude Capital Management first reported a position in Medicines Co in Q3 2013 and held it in 10 quarters.
- Prelude Capital Management's Medicines Co position peaked at $11.9M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.